References
- Frye MA. Clinical practice. Bipolar disorder – a focus on depression. N. Engl. J. Med. 364(1), 51–59 (2011).
- Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62(11), 1310–1316 (2007).
- Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61(2), 105–123 (2009).
- Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. doi:10.1007/s00406-013-0399-y (2013) (Epub ahead of print).
- Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63(8), 856–864 (2006).
- Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67(8), 793–802 (2010).
- Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol. Psychiatry 72(7), 537–547 (2012).
- Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 338(6103), 68–72 (2012).
- Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994), 959–964 (2010).
- Autry AE, Adachi M, Nosyreva E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354), 91–95 (2011).
- Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71(11), 996–1005 (2012).
- Hashimoto K. A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin. Psychopharmacol. Neurosci. 10(1), 59–60 (2012).
- Ma XC, Dang YH, Jia M et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS ONE 8(2), e56053 (2013).
- Zarate CA Jr, Mathews D, Ibrahim L et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry doi:10.1016/j.biopsych.2012.10.019 (2012) (Epub ahead of print).
- Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28(6), 631–637 (2008).
- Ibrahim L, Diaz Granados N, Jolkovsky L et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 32(4), 551–557 (2012).
- Heresco-Levy U, Gelfin G, Bloch B et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 16(3), 501–506 (2013).
- Burgdorf J, Zhang XL, Nicholson KL et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38(5), 729–742 (2013).
- Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 17(2), 112–120 (2011).
- Huang CC, Wei IH, Huang CL et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry doi:10.1016/j.biopsych.2013.02.020 (2013) (Epub ahead of print).